Augustine Asset Management Has Increased Gilead Sciences (Gild) (GILD) Holding; Intra-cellular Therapies (ITCI)’s Sentiment Is 0.96

June 23, 2018 - By Pete Kolinski

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Intra-cellular Therapies Inc (ITCI) investors sentiment decreased to 0.96 in Q1 2018. It’s down -0.50, from 1.46 in 2017Q4. The ratio is negative, as 55 investment managers increased or started new equity positions, while 57 sold and decreased stock positions in Intra-cellular Therapies Inc. The investment managers in our database reported: 38.33 million shares, up from 37.43 million shares in 2017Q4. Also, the number of investment managers holding Intra-cellular Therapies Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 40 Increased: 34 New Position: 21.

Augustine Asset Management Inc increased Gilead Sciences Inc (Gild) (GILD) stake by 21.61% reported in 2018Q1 SEC filing. Augustine Asset Management Inc acquired 9,582 shares as Gilead Sciences Inc (Gild) (GILD)’s stock declined 17.62%. The Augustine Asset Management Inc holds 53,930 shares with $4.07 million value, up from 44,348 last quarter. Gilead Sciences Inc (Gild) now has $92.41 billion valuation. The stock decreased 0.63% or $0.45 during the last trading session, reaching $71.07. About 4.11 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 23, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 30/05/2018 – GALAPAGOS NV – FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED; 05/03/2018 – GLAXOSMITHKLINE PLC – DOLUTEGRAVIR WAS WELL-TOLERATED IN HIV/TB CO-INFECTED ADULTS RECEIVING RIFAMPIN-BASED TB THERAPY; 01/05/2018 – Gilead Sciences Announces Second Quarter 2018 Dividend; 06/03/2018 – Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD; 30/04/2018 – AbbVie’s Mavyret Rises After 1-Wk Fall, Epclusa Advances: Hep-C; 15/05/2018 – Gilead Presenting at Bank of America Conference Tomorrow; 30/05/2018 – GILEAD, GALAPAGOS: EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20; 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 25/04/2018 – CAFC: GILEAD SCIENCES, INC. v. MERCK & CO., INC. [OPINION] – Appeal #16-2302 – 2018-04-25; 05/03/2018 – ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With

Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It increased, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Sun Life Fincl has invested 0% in Gilead Sciences, Inc. (NASDAQ:GILD). 1,064 are owned by West Oak Limited Liability Company. Strs Ohio has invested 0.31% in Gilead Sciences, Inc. (NASDAQ:GILD). Brookmont Capital Mngmt stated it has 33,527 shares. Rfg Advisory Lc, Alabama-based fund reported 5,727 shares. Moreover, First Mercantile Tru has 0.06% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Chickasaw Cap Mngmt has invested 0.04% in Gilead Sciences, Inc. (NASDAQ:GILD). Suntrust Banks invested 0.06% in Gilead Sciences, Inc. (NASDAQ:GILD). Vident Inv Advisory Ltd Liability Co owns 74,928 shares or 0.23% of their US portfolio. Aqr Cap Mgmt Lc accumulated 10.65M shares. Moreover, Woodley Farra Manion Port Mgmt has 3.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 358,413 shares. Tcw Group invested 1.43% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Gm Advisory Gru accumulated 3,019 shares. Daiwa Sb Invests owns 0.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 480 shares. Palisade Mngmt Ltd Company Nj owns 0.02% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 8,235 shares.

Since January 2, 2018, it had 0 insider buys, and 23 sales for $48.21 million activity. $437,067 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Cogan John Francis. 50,000 shares were sold by MARTIN JOHN C, worth $4.18M. Alton Gregg H sold $1.18M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, February 20. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, February 21. Another trade for 100,000 shares valued at $8.02 million was made by Meyers James R on Tuesday, January 16. WILSON GAYLE E also sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Does Gilead Have An HBV Blockbuster Drug In The Works?” on June 19, 2018, also Seekingalpha.com with their article: “Gilead Oncology CAR T-Cell Therapies Outlook Compelling” published on June 18, 2018, Seekingalpha.com published: “Gilead: Growth Pick For Your Portfolio” on June 15, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)” published on June 13, 2018 as well as Seekingalpha.com‘s news article titled: “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” with publication date: May 30, 2018.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. William Blair initiated the stock with “Buy” rating in Thursday, August 31 report. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, July 29. BMO Capital Markets upgraded the shares of GILD in report on Wednesday, November 2 to “Outperform” rating. As per Monday, August 17, the company rating was upgraded by Vetr. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Robert W. Baird on Friday, September 15. Maxim Group maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, February 12. Maxim Group has “Buy” rating and $115 target. The firm has “Hold” rating by Maxim Group given on Monday, August 28. The rating was initiated by Oppenheimer with “Hold” on Wednesday, October 4. The stock has “Hold” rating by Jefferies on Friday, October 27. Morgan Stanley maintained it with “Equal-Weight” rating and $103 target in Thursday, May 26 report.

Ratings analysis reveals 50% of Intra-Cellular Therapies’s analysts are positive. Out of 4 Wall Street analysts rating Intra-Cellular Therapies, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ITCI was included in 4 notes of analysts from September 29, 2016. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Overweight” rating given on Friday, December 16 by Cantor Fitzgerald. The firm earned “Neutral” rating on Thursday, September 29 by SunTrust. The firm earned “Mkt Perform” rating on Thursday, September 29 by JMP Securities. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, September 29 report.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on August, 8. They expect $-0.77 EPS, down 87.80% or $0.36 from last year’s $-0.41 per share. After $-0.65 actual EPS reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts 18.46% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 9 insider sales for $1.97 million activity.

More recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: Nasdaq.com which released: “Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms …” on May 31, 2018. Also Globenewswire.com published the news titled: “Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical …” on May 29, 2018. Streetinsider.com‘s news article titled: “Intra-Cellular Therapies (ITCI) Highlights Data on Symptom Improvement by Lumateperone on Negative Symptoms …” with publication date: May 31, 2018 was also an interesting one.

Rhenman & Partners Asset Management Ab holds 2.06% of its portfolio in Intra-Cellular Therapies, Inc. for 792,730 shares. Bb Biotech Ag owns 2.20 million shares or 1.28% of their US portfolio. Moreover, Clough Capital Partners L P has 1.01% invested in the company for 499,624 shares. The Utah-based Wasatch Advisors Inc has invested 0.51% in the stock. Pointstate Capital Lp, a New York-based fund reported 1.87 million shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>